Viatris Inc., Pfizer Inc. and Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.) are Dominating the Global Dengue Treatment Market in 2020

Global Dengue Treatment Market is expected to grow with the CAGR of 25.5% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-dengue-treatment-market

Global dengue treatment market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in the global dengue treatment market are introducing strong range of products provider along with pipelines products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio. For instance, In June 2017, Sun Pharmaceutical Industries Ltd. announced that they have joined hands with NIV for combating Zika Virus, Dengue, and chikungunya. Under this, the major company provided the molecules to NIV for testing on these particular diseases. This will increase the R&D activity for the company and will in future increase the company product portfolio for the dengue treatment market.

Viatris Inc. is the dominating player in global dengue treatment market. The other key players existing in the market includes Pfizer Inc., Teva Pharmaceuticals USA, Inc., Perrigo Company plc, GlaxoSmithKline plc, Dr. Reddy’s Laboratories Limited, Fresenius Kabi USA, Sun Pharmaceutical Industries Ltd., ABIVAX, Aurobindo Pharma, Baxter, EMERGEX VACCINES, Hikma Pharmaceuticals PLC, Sanofi, Takeda Pharmaceutical Company Limited, among others.

Dengue Treatment Market Viatris Inc.

Viatris Inc. was incorporated in 2020 and is headquartered in Pennsylvania, the U.S. The company is mainly works in the healthcare domain with the production of drugs including prescription generic, branded generic, brand-name and biosimilar drugs, as well as over-the counter remedies. The products in the market are legacy mylan products, legacy upjohn products, legacy greenstone products among which legacy mylan products is the marketr focussed category.

For instance;

  • In November 2020, Viatris Inc. was launched as a combination of two Mylan N.V and Pfizer Upjohn business. This combination of the two will focus on improving patient health. Viatris Inc. has the scientific, production and distribution expertise with proven medical, regulatory, and global commercial capabilities to provide high-quality medicines to patients in more than 165 countries and territories. This launch of a new company will increase the revenue of the company in near future.

The company has presence across North America, Europe, South America, Asia-Pacific, Middle East and Africa.

Pfizer Inc.

Pfizer Inc. is headquartered in New York, U.S. The company was incorporated in 1849. The company is focused on addressing the drug discovery solutions in different disease stage and serving the pharmaceutical and biotechnological companies worldwide. The company provide medication under consumer healthcare such as ceftriaxone and ciprofloxacin. The business segments in the market biopharma, upjohn, consumer healthcare among which consumer healthcare is the market focused segment. The product categories are Accupril, Accuretic, Adenosine, Bacitracin, Bavencio, Caduet, Ciprofloxacin, Cisatracurium Besylate, Dacarbazine, Daptomycin, Elelyso, Eliquis, Feldene, Fentanyl Citrate, Gelfilm, Gemcitabine, Halcion, Kemadrin, Labetalol Hydrochloride, Magnesium Sulfate, Nafcillin, Ceftriaxone among which Ciprofloxacin, Ceftriaxone is the market focused category.

  • In December 2019, Pfizer Inc. foundation “Global Health Innovation” has donated to fight dengue in South East Asia with an amount of USD 100,000 to support community-based initiatives focused on combatting infectious disease through programs aimed at strengthening health systems at the community and primary care level. This will increase the company's focus on dengue treatment and research development.

The company has wide presence across North America, South America, Europe, Asia-Pacific, Middle East and Africa. The company has subsidiaries such as Pfizer Animal Health B.V. (Netherlands), Pfizer Asia International B.V. (Netherlands), Pfizer Australia Superannuation Pty Ltd (Australia), Pfizer Dominicana, S.A. (Dominican Republic) and Pfizer Egypt S.A.E. (Egypt) among others.

Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.)

Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.) was founded in 1901 and is headquartered in New Jersey, U.S. The company is focused on helping patient around the world to access affordable medicines and benefit them from the innovation to improve health of the patient with specialty generics, biopharmaceutical medications and provide product under generics medication.

For instance-

  • In May 2020, Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.) announced that had kept an eye for the strategic focus for Japan joint venture to meet the unmet demand of the generics in Japanese Market. This will help the company to increase the market share for their generics products and will help in net sales and revenue.

The company has wide presence across U.S.